Why Edgewise Therapeutics (EWTX) Is Up 6.4% After Long-Term Sevasemten Becker Data - And What's Next

Edgewise Therapeutics recently presented long-term data from its MESA open-label extension study of investigational drug sevasemten in Becker muscular dystrophy, showing sustained stabilization of ...

Edgewise Announces Positive Long-Term Sevasemten Data Demonstrating Sustained Functional Stabilization in Becker Muscular Dystrophy Through 3.5 Years of Follow-Up

Edgewise Therapeutics, Inc. (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today presented at the 2026 ...